End-to-End Case: A Variant's Journey from Discovery to Clinical Report

Gains:

• Ability to combine all parts learned throughout the module (sequence, variant, structure, literature, clinical) in a single end-to-end AI-supported workflow
• Ability to apply the principle of 'artificial intelligence produces, human verifies and vouches' and primary source verification at every step
• Ability to manage the verification chain by documenting confidentiality and final expert approval in an end-to-end case

In this module, we discussed each stage separately, from sequence analysis to protein structure, from CRISPR to omics, from literature to ethics and confidentiality. In this final unit, we combine them all into one realistic workflow: the journey of a variant found in a patient, from raw data to an approved clinical report. The goal is to holistically see how to position artificial intelligence (AI) as an end-to-end assistant and how verification and human accountability are intertwined at every stage.

Our scenario (fictional): A 34-year-old female patient comes for genetic evaluation with a family history of breast cancer at an early age. A variant in the BRCA1 gene was found in the panel test. Our mission: classify this variant, interpret its possible impact on the protein, review the literature, and draft a clinical report — using AI at every step and validating it at every step.

Phase 1: Fixing the variant and privacy control

At the very beginning of the workflow, we do two things: standardize the data and ensure confidentiality.

Privacy first: The patient's name, identification number, and date of birth do not enter any open AI tools (Unit 10). We only work with the variant, the genome version, and the transcript — and only if the variant does not identify the individual. Then we fix the variant: GRCh38, BRCA1, NM_007294.4, for example c.5266dupC (p.Gln1756fs). We confirm this with a validator (VariantValidator); We do not accept the representation given by AI at face value (Unit 1, 3).

Stage 2: Gathering evidence (Unit 3)

We have the AI build the ACMG proof framework — but without making the class tell it. Then we verify each piece of evidence ourselves:

• gnomAD frequency: We look for the variant in gnomAD and see that it is very rare/absent (in the direction of PM2).
• ClinVar: We open the record and check existing comments and freshness.
• Variant type: If a frameshift leads to premature cessation, there may be strong evidence of loss of function (PVS1) — but we evaluate this in the context of the gene and transcript.

We do not use any frequency or reference given by AI without verifying it (Unit 9).

Stage 3: Protein-structure interpretation (Unit 4)

To understand the effect of the variant on the protein, we download the AlphaFold structure (with its UniProt number), look at the pLDDT confidence score and UniProt functional annotations of the affected region. Because a frameshift changes much of the protein, the structure interpretation may support the loss-of-function hypothesis here—but the structure is a guess, not definitive proof. We don't ask the AI ​​for coordinates; We read from the file.

Stage 4: Literature verification (Unit 7)

We get search terms from the AI, search it on PubMed itself, and find actual articles on the variant and the gene. We verify the citations that the AI ​​submits “from memory” with the DOI/PMID. We preserve the distinction between relationship and causality at the source.

Stage 5: Classification and clinical interpretation (Units 3, 8)

We combine the validated evidence, inferring the probable class with the combination of ACMG (in this example, strong loss-of-function and rarity evidence may be in the direction of “pathogenic/probably pathogenic” — but the expert has the final say). We combine clinical interpretation with phenotype and family history: is the patient's picture consistent with BRCA1? If there is uncertainty, we state it honestly.

Stage 6: Report draft and approval (Unit 8)

With AI, we prepare draft reports for the physician and the patient; In a language that does not exaggerate causality, is clear about uncertainty, and directs to genetic counseling. Expert confirms every sentence. We add the limits section (what the test does not cover, reevaluation conditions).

Tip: When inputting the output of each stage into the next in an end-to-end flow, make sure that output is validated. An unverified frequency or attribution is carried forward incorrectly to all subsequent stages (chained hallucination—Unit 9).

workflow table

Stage

Role of AI

Mandatory verification

decision maker

fixing

demo sketch

VariantValidator

expert

Privacy

Anonymization control

human control

expert

evidence

Setting up a framework

gnomAD, ClinVar

expert

structure

Comment

pLDDT, file

expert

literature

Search term, summary

DOI/PMID

expert

class

combination draft

ACMG rules

expert

Report

language draft

approval sentence by sentence

Expert/Consultant

Three mini cases (breakpoints in the flow)

Case 1 — Incorrect transcript. One team worked with the transcript given by the AI ​​at the beginning of the stream; he later realized the panel had used a different transcript. c. Their positions had shifted. The error was resolved by fixing from the beginning with VariantValidator. Lesson: error in the fixing phase disrupts the entire flow.

Case 2 — Fake supporting article. In the literature phase, AI proposed a persuasive paper supporting the classification. PMID check showed that the article did not exist; removed from the chain of evidence. The actual evidence was sufficient, but academic/clinical trust would have been damaged if the false attribution remained in the report.

Case 3 — Confirmation gained. At the reporting stage, the AI ​​draft included the statement "this variant definitely causes cancer." The consultant corrected this by saying "this variant significantly increases the risk of breast/ovarian cancer, but does not indicate definitive disease" and added a recommendation for genetic counseling. Tone and accuracy were shaped in expert hands.

Two copyable templates (end to end)

1) Flow planner:

Your role: clinical genetics workflow assistant. Create an end-to-end checklist from discovery to report for the following variant: [genome version, gene, transcript, HGVS]. Write at each stage (fixation, privacy, evidence, structure, literature, class, report) with columns "What does the AI ​​do / what do I verify / who decides". YOU make the class and clinical decision.

2) Final inspection:

Pre-check the following completed variant comment and report draft before submission: [content]. Check for: unconfirmed frequency/attribution, exaggerated causality/precision statement, missing ambiguity warning, missing boundary division, privacy vulnerability. List each problem and any suggestions for fixing it.

Weak prompt / Strong prompt

Weak: “Write a complete clinical report for this BRCA1 variant.”

Problem: AI produces “report” by fitting all the stages in one go; frequency, attribution, class, clinical judgment are all unconfirmed.

Strong: "Make a checklist from discovery to report for this BRCA1 variant; separate out at each stage what you will do, what I will verify, and who will make the decision. I will make the class and clinical decision after confirming the evidence."

Why it's powerful: The flow is structured, each stage is tied to validation, and the decision and responsibility remain with the human.

Common mistakes

• Asking for a "finished report" with one prompt. Stages are combined without verification; error accumulates.
• Ignoring the fixing phase. Incorrect version/transcript refutes the entire stream.
• Moving output between stages without validating it. A chain hallucination arises.
• Thinking about privacy at the "end" of the flow. Confidentiality must be established in the first place, at data entry.
• Leaving the decision and tone to the AI. Classroom and clinical messaging must be approved by the specialist.

Caution: Using end-to-end AI saves a lot of time but does not reduce responsibility; On the contrary, it makes the discipline of verification at each stage even more important. AI speeds up the flow; Human guarantees accuracy, security and ethical compliance.

Depth: workflow time savings, fragility and audit trail

The real value of end-to-end flow is not “let the AI ​​do it all” but in gaining time in the right places and slowing down in the right places. Let's quantify the gain in this scenario: setting up the evidence framework, generating search terms, simplifying the report language, and coming up with a post-audit checklist can cut what would traditionally take several hours of drafting work into tens of minutes. In contrast, gnomAD/ClinVar validation, VariantValidator pinning, DOI checking, and expert judgment cannot be abbreviated — they are the security backbone of the stream. Correct mindset: “AI produces draft, human acts as guarantor.” Profit is in the draft, responsibility is in the decision.

The most fragile link in the flow is always the first: anchoring. The wrong genome version or wrong transcript silently propagates to each subsequent stage, eventually producing a completely invalid report. So don't proceed to the next step without validating the anchor with a single standalone tool (like VariantValidator). The second most vulnerable point is output carryover between stages: making the unverified output of one stage the input to the next invites chain hallucination.

Finally, in the clinical context, the audit trail is integral to the flow: it must be documented which source was checked on which date, which ClinVar version was seen, who approved which decision. ClinVar reviews change over time; A record that is "pathogenic today" may have regressed to VUS a year later. The audit trail enables both re-evaluation and legal/ethical accountability.

streaming feature

principle

Application

time saving

Get up to speed on the draft

Framework, language, checklist from AI

Fragility

Secure the first ring

Confirm fixation with independent tool

Output transport

Move without verification

Every stage is approved at the source

audit trail

Document every decision

Source, date, approved by registered

In summary

• A variant's journey from discovery to report; It covers the stages of fixing, confidentiality, evidence, structure, literature, class and report.
• AI produces draft/code/summary at each stage; At each stage, the expert verifies and decides.
• Output between stages should be moved to the next only after verification.
• Confidentiality is established from the very beginning; Class and clinical decision is finally made with expert approval.

Application task

Choose a fictional variant (e.g. a well-known BRCA1 record). 1. Create an end-to-end checklist with the template and carry out each stage yourself in the method of the corresponding unit in this module: fix the variant, check gnomAD/ClinVar, look at the AlphaFold structure, find a real article, justify the possible class and draft a report paragraph and proofread it with an expert eye. Try to find a difference between the AI ​​and the source in at least two stages.

checklist

• [ ] I set up privacy from the beginning; I did not transfer any identifying data.
• [ ] I fixed the variant with the version/transcript and confirmed it with the validator.
• [ ] I verified each evidence (frequency, ClinVar, literature) in the primary source.
• [ ] I made the structure comment with confidence score and from the file.
• [ ] I have personally validated the class and clinical interpretation based on evidence.
• [ ] I checked causality/precision in the report language and added bounds.

Module Exam

1. Which of the following is the most accurate positioning for artificial intelligence (especially the big language model) in molecular biology and genetics?

• A) It is an assistant who writes code, produces drafts and comments; Every biological phenomenon must be verified in the primary source, final interpretation belongs to the expert ✔
• B) It is a reliable genome database; The sequences and variants given can be written directly to the report.
• C) Since it measures like a laboratory instrument, its outputs are considered experimental evidence.
• D) It is competent to finalize the clinical pathogenicity decision without human approval.

Explanation: The large language model is not a genome database or laboratory tool; It is a text generator that statistically imitates the texts in the training data. Biological facts such as sequence/variant/gene should always be verified from primary sources such as NCBI, Ensembl, ClinVar, gnomAD; The final clinical and scientific interpretation should belong to the competent expert.

2. You received the genome coordinate of a variant from the AI, but your project uses GRCh38 (hg38). Artificial intelligence may have given the hg19 coordinate. What is the right approach?

• A) Using the coordinate directly because it seems reasonable
• B) There is no need to ask for the version as artificial intelligence always gives the most current version.
• C) Explicitly confirm the genome version and verify the coordinate with an official liftOver tool ✔
• D) Since the difference between hg19 and hg38 is insignificant, choose one and continue

Description: Coordinates shift between genome versions (GRCh37/hg19 and GRCh38/hg38). Any coordinates given without a version are suspect. Coordinates should be transformed/verified with an official liftOver tool and the genome version used should be clearly confirmed; otherwise the entire alignment and comment will point to the wrong location.

3. In HGVS notation 'c.', 'p.' and 'g.' What do the prefixes mean and why should they not be confused?

• A) All three mean the same thing, it does not matter which one is used.
• B) 'c.' coding DNA/transcript, 'p.' protein, 'g.' is the genomic level; If confused, it may indicate a different location ✔
• C) 'p.' always 'c.' is three times its value, the conversion is automatic and error-free
• D) Prefixes are merely formal; There is no need to specify the transcript version

Description: HGVS is the standard spelling format with variants: 'c.' coding DNA (transcript) level, 'p.' protein level, 'g.' refers to the genomic level. Mixing these up or using the wrong transcript version may indicate an entirely different locus/variant; therefore the correct prefix must be used along with the transcript version (e.g. NM_007294.4).

4. What should be the role of AI when using ACMG criteria to assess the pathogenicity of a variant?

• A) Artificial intelligence finalizes evidence and class; no need for expert supervision
• B) GnomAD control is unnecessary since artificial intelligence gives the population frequency from its memory.
• C) Since ACMG criteria are strict, the AI output is automatically considered correct
• D) Artificial intelligence can produce draft evidence; Every evidence should be verified in the primary source, the final classification should be made by the expert ✔

Description: ACMG is a framework that classifies variant pathogenicity by categories of evidence (population frequency, in silico prediction, segregation, functional study, literature). AI can produce draft evidence; However, each evidence must be personally verified in ClinVar, gnomAD and the literature, and the final classification (pathogenic/likely pathogenic/VUS...) must be made by the competent expert.

5. You will work with a DNA sequence given by artificial intelligence. What is the best first step?

• A) Using the sequence by obtaining it from a primary source such as NCBI/Ensembl or confirming it with the reference there ✔
• B) Inserting the sequence directly into analysis because it appears to be the correct length
• C) Assuming the sequence is correct if the letters consist of valid nucleotides
• D) Ask the artificial intelligence about the sequence once again and count it as correct if the two outputs are the same.

Explanation: AI can 'fill in' a string it doesn't remember with plausible-looking letters; Even if the length and letters appear correct, they may not match the actual reference. Therefore, any sequence given by artificial intelligence from the head is not used directly; the sequence is taken from a primary source such as NCBI/Ensembl or confirmed by reference therein.

6. What does the pLDDT score mean in protein structure prediction from a tool like AlphaFold?

• A) It is a certificate showing that the structure has been experimentally proven
• B) It is a laboratory value that measures the functional activity level of the protein.
• C) It is a score indicating the model's confidence in the local structure prediction for each residue; lower value is flexible/unreliable zone ✔
• D) It is a ratio that shows the variant frequency of the protein in the population.

Description: pLDDT (0-100) is a confidence score that indicates how confident AlphaFold is in its local structure prediction for each residue (amino acid). High pLDDT means reliable local structure, low pLDDT means flexible/disordered or unreliable region. The structure is a guess; low-confidence regions should not be over-interpreted and functional claims should be supported by experimental evidence.

7. Why is it risky to claim that a mutation 'absolutely disables' the protein based on an AlphaFold structure prediction?

• A) AlphaFold structures cannot be used for any purpose because they are always wrong
• B) The structure is a guess; functional claims are at the level of hypotheses and require experimental verification ✔
• C) There is no risk; AlphaFold output is as accurate as experimental build
• D) There is risk only if pLDDT is low; If it is high, the claim is automatically considered proven.

Disclosure: AlphaFold is a structure prediction, not experimental proof; It is particularly limited in flexible/disordered regions and in modeling mutation effects. Functional claims based on a construct are at the hypothesis level and require experimental verification (e.g., functional study). Otherwise, the prediction is presented as evidence.

8. What is the most critical validation step regarding CRISPR gRNA (guide RNA) candidates suggested by artificial intelligence?

• A) If the length of the gRNA is correct, no further checks are required
• B) If the artificial intelligence says 'off-target effect is low', proceed directly to the experiment
• C) It is sufficient assurance that the gRNA sequence consists of valid nucleotides
• D) Validate candidates with true genome alignment and expert off-target analysis tools and confirm in the laboratory ✔

Description: gRNA is the guide RNA that directs the Cas enzyme to the target; With the wrong design, it can also cut off-target areas. Candidates returned by AI must be validated by actual genome alignment and expert off-target analysis tools, then confirmed by laboratory experimentation. Just because artificial intelligence says 'safe' is not a substitute for verification.

9. Why is multiple testing correction (e.g. FDR/Benjamini-Hochberg) necessary when testing differences in expression of thousands of genes with RNA-seq?

• A) Thousands of simultaneous tests inflate false positives; FDR correction limits these, raw p-value is misleading ✔
• B) Correction is only necessary if the number of samples is small; It has nothing to do with the number of genes
• C) Multiple testing correction does not change the result, it is only formal
• D) Crude p<0.05 is always sufficient; correction makes statistics unnecessarily difficult

Explanation: When thousands of genes are tested simultaneously, many genes come up with p<0.05 (false positive) due to chance alone. Multiple testing correction (FDR - false discovery rate control) limits these false positives. Lists of genes declared 'significant' with uncorrected p-values ​​are misleading; The adjusted value (q-value) should be used.

10. What does it mean if a pathway is found to be 'significantly enriched' in a pathway enrichment analysis and how should it be interpreted?

• A) Proves that the pathway is the definitive cause of the disease
• B) It is experimental evidence that the pathway is active in the cell
• C) It is a statistical signal indicating that pathway genes are overrepresented than expected; Requires critical interpretation, not causality ✔
• D) It is a sufficient result on its own, independent of background and multiple testing correction

Description: Enrichment is a statistical signal that indicates that a particular pathway is overrepresented among genes whose expression changes; It is not proof of causality or that the pathway is actually active. Conclusion; The gene set used must be interpreted critically in the context of background selection and multiple testing correction and with biological plausibility.

11. When giving a literature summary, AI may cite an article that appears real but does not exist (fake citation). What is the right approach?

• A) If the author and journal name are realistic, the citation is probably correct, checking is unnecessary
• B) Verify each citation in the primary source via DOI/PubMed; ✔ not using what cannot be found
• C) Artificial intelligence does not make up attribution; His references can be added directly to the bibliography
• D) If there are many citations, it is not a problem if a few of them are wrong.

Description: AI can produce a completely made-up article (and fake DOI) with real-sounding author names in a real journal. Each citation must be personally verified at the primary source via DOI/PubMed; References that cannot be found should not be used. Scientific responsibility belongs to the author; No unverified references should enter the text.

12. What is the most accurate principle regarding drafting an AI-generated clinical genetic report?

• A) If the draft is fluent, it can be given directly to the patient
• B) No separate source verification is required as AI also generates evidence
• C) The pathogenicity decision in the report can be left to artificial intelligence, the expert only checks the format
• D) Each clinical claim must be substantiated, the final report must be approved by the competent specialist, and the chain of verification must be documented ✔

Description: Artificial intelligence saves time in producing report drafts and summaries; However, each clinical claim must be linked to evidence and primary sources, and the final report must be approved by the authorized expert. AI output cannot be directly translated into a patient decision; The verification chain must be documented.

13. What does it mean if the AI's output sounds very fluid and 'confident'?

• A) Confident tone is not evidence of accuracy; The need for validation increases, not decreases ✔
• B) A fluent and decisive answer is most likely true, confirmation is unnecessary
• C) Confident tone indicates the model is reading data directly from memory
• D) Tone is a measure of confidence, as hesitant answers are wrong and confident answers are right.

Explanation: The AI's confident tone is not evidence of accuracy; The most dangerous hallucinations come with the most fluent and convincing sentences. When the confident tone is seen, the need for verification increases, not decreases. Each fact (sequence, variant, gene, reference) should be cross-validated with an independent primary source.

14. What is the most important privacy precaution before giving a patient's genetic data to a publicly available AI tool for analysis?

• A) If the data is encoded in base64, it can be pasted safely
• B) If only the patient's name is deleted, no further action is required
• C) Not providing personally identifiable data at all; anonymization, data minimization and consent/observe the legal framework ✔
• D) Genetic data can be shared freely because it is not considered personal data.

Description: Genetic data is a special category of personal data and an individual can be re-identified with rare combinations of variants. Identifiable genetic data is never provided to open tools; data should be anonymized, only the minimum necessary information should be shared (data minimization) and consent/legal framework (KVKK/GDPR) should be observed.